Neluxicapone

Neluxicapone ( ) is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Neluxicapone ( ) is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024. The drug is a nitrocatechol and is structurally related to other catechol COMT inhibitors like entacapone, tolcapone, and nebicapone. COMT inhibitors are used in conjunction with levodopa in the treatment of Parkinson's disease.

Neluxicapone was first described in the literature by 2018. Its was designated by the World Health Organization (WHO) in 2019.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1337497821 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.